Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...

On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than ... three years while it aims to get ...

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.

The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been ...

Unlike tobacco, however, the links between cancer and other health conditions and junk ... uncertainty' behind excess deaths ...

The primary endpoint is relative efficacy of Vaxart's COVID-19 vaccine candidate compared to an approved mRNA COVID-19 vaccine for the prevention ... approach to prevent the progression to cervical ...

Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...

As the pandemic has shown, mRNA vaccines can be developed very quickly ... has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

who opposes mRNA covid vaccines and rejected well-established disease control practices during a measles outbreak; Johns ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled.